盐酸氨溴素与异丙托溴铵雾化吸入治疗对慢性阻塞性肺病患者肺功能及病程的影响

目的 :探讨异丙托溴铵和盐酸氨溴素在慢性阻塞性肺疾病 (COPD)治疗中的作用。方法 :将COPD住院患者 4 7例随机分成两组 ,除常规治疗外 ,第一组 (2 5例 )辅加异丙托溴铵 0 .5mg 生理盐水 3ml雾化吸入 ;第二组 (2 2例 )辅加盐酸氨溴素 15mg 异丙托溴铵 0 .5mg 生理盐水 1ml雾化吸入 ,治疗前及治疗 3d后测定FEV1。结果 :第二组治疗提升FEV1的作用显著强于第一组 (P <0 .0 5 ) ,并使平均住院日显著缩短 (P <0 .0 5 )。结论 :盐酸氨溴素与异丙托溴铵联合雾化吸入治疗COPD具有协同作用 ,优于单一异丙托溴铵。

THE INFLUENCES OF NEBULIZING INHALATION OF AMBROXOL HYDROCHLORIDE (MUCOSOLVAN) AND IPRATROPIUM BROMIDE (ATROVENT) ON THE LUNG FUNCTION AND CLINICAL COURSE OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Objective:To study the role of Ipratropium Bromide and Ambroxol Hydrochoride in the treatment of chronic obstructive pulmonary disease(COPD).Methods:47 cases of male patients with COPD (exacerbation phrase)were grouped randomly. Except for ordinary treatment, Group 1 patients (25 cases)were treated with nebulizing inhalation of Ipratropium Bromide(Atrovent),group 2 patients(22 cases)were treated with nebulizing inhalation of Ipratropium Bromide and Ambroxol Hydrochoride(Mucosolvan). Results:Group 2 patients had significantly higher increasement of FEV 1 and significantly shorter average hospitalizing days than group 1 patients.Conclusions:Combined use of Ipratropium Bromide and Ambroxol Hydrochoride has synergistic action for the treatment of COPD.